$599

Farxiga HF Fast Track Designation; New Novo/Medtronic and Sanofi/Abbott Partnerships

With the start of the 2019 EASD conference, a series of diabetes drug and device-related press releases have been observed including connected care partnerships between Novo/Medtronic and Sanofi/Abbott. Additionally, AstraZeneca announced that FDA granted Fast Track designation for dapagliflozin in worsening heart failure. Below FENIX insights and context from each respective announcement.

This content is for Read Less members only.
Register
Already a member? Log in here